ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Allergan licenses AstraZeneca drug

by Ann M. Thayer
October 10, 2016 | APPEARED IN VOLUME 94, ISSUE 40

Allergan will pay $250 million up front and up to $1.3 billion more in milestone payments over 15 years for rights to the AstraZeneca anti-IL-23 monoclonal antibody MEDI2070. AstraZeneca will pay one-third of the money it receives to Amgen, its partner in developing MEDI2070. The antibody is in Phase IIb clinical trials for treating Crohn’s disease and is ready to enter Phase II trials for ulcerative colitis. AstraZeneca says the target diseases fall outside its focus areas.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment